Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 9 July 2024

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the quality, safety, and efficacy of therapeutic goods in Australia. This legislation aimed to fill the gap left by the need for a comprehensive framework governing the manufacturing, supply, and advertising of therapeutic goods to ensure they meet necessary health and safety standards. The Act provides the Therapeutic Goods Administration (TGA) with the authority to oversee and enforce compliance with these standards, protecting public health by ensuring that only therapeutic goods that meet acceptable standards are available on the market. The TGA, a part of the Department of Health and Aged Care, administers the Act with the policy objective of maintaining and improving the health of Australians by regulating therapeutic goods and ensuring they are safe and of high quality. This publication of the list of manufacturers suspended from licensing for the manufacture of therapeutic goods exemplifies the Act's application in maintaining these standards by allowing the TGA to temporarily suspend licences when necessary to protect public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of persons and entities involved in the manufacture, supply, importation, exportation, and advertising of therapeutic goods in Australia. This encompasses pharmaceutical and medical devices, as well as other health-related products such as vitamins, complementary medicines, and blood products. The Act applies to manufacturers, suppliers, importers, and exporters of these goods, and it covers the entire supply chain, including wholesalers, retailers, and distributors. The geographic reach of the Act is national, extending across the Commonwealth of Australia, including states and territories, ensuring a unified regulatory framework for therapeutic goods throughout the country. The Act provides for certain exclusions, such as goods exempted by regulations, and it sets thresholds for the types of products that require specific types of authorisation. The Act may also extend or restrict application through subordinate instruments, such as regulations or determinations, which further define the scope and specific requirements for certain therapeutic goods.

Key Provisions

The Therapeutic Goods Administration (TGA), under Section 41(1)(d) of the Therapeutic Goods Act 1989, has issued a notice suspending the licences of several manufacturers of therapeutic goods. The suspended licences include those of LITTLE GREEN PHARMA, HERBAL-ID, GOLD COAST LABORATORIES PTY LTD, GLOBAL MEDICAL SOLUTIONS AUSTRALIA PTY LIMITED, ROYAL ADELAIDE HOSPITAL RADIOPHARMACY, and Veolia Environmental Services (Australia) Pty Ltd. The suspensions are in effect from dates ranging from 25 June 2024 to 1 January 2026, depending on the entity involved. The suspensions were made at the request of the manufacturers themselves. These suspensions impose certain obligations on the affected manufacturers, primarily prohibiting them from manufacturing therapeutic goods during the suspension period. The suspension effectively bars the entities from producing, supplying, or advertising therapeutic goods unless explicitly permitted by the TGA. The manufacturers must also cease any ongoing manufacturing activities related to therapeutic goods. Additionally, the entities must comply with any specific conditions set forth in the suspension notices, which could include submitting reports or undergoing audits to ensure compliance with regulatory standards. Failure to comply with the suspension order can result in severe consequences. Under the Therapeutic Goods Act 1989, any breach of the suspension order may lead to enforcement actions, including fines and potential legal proceedings. For instance, manufacturing or supplying therapeutic goods during a suspension period could result in penalties of up to $1.1 million for a corporation and $220,000 for an individual, as per the Act. Additionally, ongoing non-compliance might lead to criminal charges, with the possibility of imprisonment. The severity of the penalties underscores the importance of adhering to the TGA’s directives to ensure public health and safety.